CN1287166A - 人原始间叶干细胞群的分离、体外培养、制备及应用 - Google Patents
人原始间叶干细胞群的分离、体外培养、制备及应用 Download PDFInfo
- Publication number
- CN1287166A CN1287166A CN 99117589 CN99117589A CN1287166A CN 1287166 A CN1287166 A CN 1287166A CN 99117589 CN99117589 CN 99117589 CN 99117589 A CN99117589 A CN 99117589A CN 1287166 A CN1287166 A CN 1287166A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- stem cell
- cell
- human
- cell population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 141
- 238000000926 separation method Methods 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 138
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 230000004069 differentiation Effects 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 18
- 210000002966 serum Anatomy 0.000 claims abstract description 17
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims abstract description 12
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 10
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 10
- 210000002435 tendon Anatomy 0.000 claims abstract description 4
- 238000010361 transduction Methods 0.000 claims description 29
- 230000026683 transduction Effects 0.000 claims description 29
- 241000700605 Viruses Species 0.000 claims description 26
- 108010047761 Interferon-alpha Proteins 0.000 claims description 25
- 210000000988 bone and bone Anatomy 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 22
- 230000012010 growth Effects 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- 238000012239 gene modification Methods 0.000 claims description 13
- 230000005017 genetic modification Effects 0.000 claims description 13
- 235000013617 genetically modified food Nutrition 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 12
- 210000001612 chondrocyte Anatomy 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 244000309466 calf Species 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000011132 hemopoiesis Effects 0.000 claims description 10
- 210000003725 endotheliocyte Anatomy 0.000 claims description 9
- 238000001415 gene therapy Methods 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 230000036039 immunity Effects 0.000 claims description 9
- 230000001177 retroviral effect Effects 0.000 claims description 9
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 8
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 229960003957 dexamethasone Drugs 0.000 claims description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 210000000107 myocyte Anatomy 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 7
- 102000013275 Somatomedins Human genes 0.000 claims description 7
- 210000001772 blood platelet Anatomy 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 7
- 201000006938 muscular dystrophy Diseases 0.000 claims description 7
- 238000001890 transfection Methods 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 238000012637 gene transfection Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 208000009292 Hemophilia A Diseases 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 229940044627 gamma-interferon Drugs 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- 102000002070 Transferrins Human genes 0.000 claims description 4
- 108010015865 Transferrins Proteins 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- -1 antimycoin Chemical compound 0.000 claims description 4
- 238000010322 bone marrow transplantation Methods 0.000 claims description 4
- 238000003501 co-culture Methods 0.000 claims description 4
- 238000009795 derivation Methods 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 150000002505 iron Chemical class 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 229960004232 linoleic acid Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000011164 ossification Effects 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 210000002536 stromal cell Anatomy 0.000 claims description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 3
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 3
- 108090000394 Erythropoietin Proteins 0.000 claims description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 108010013709 Leukocyte Common Antigens Proteins 0.000 claims description 3
- 102000017095 Leukocyte Common Antigens Human genes 0.000 claims description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 229940050528 albumin Drugs 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- MUTOERQVXAXVTM-UHFFFAOYSA-N 3-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CC(C)C)C2=C1NC=N2 MUTOERQVXAXVTM-UHFFFAOYSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 102100030703 Interleukin-22 Human genes 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 235000018259 Solanum vestissimum Nutrition 0.000 claims description 2
- 240000002825 Solanum vestissimum Species 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 2
- 102000058223 human VEGFA Human genes 0.000 claims description 2
- 102000019207 human interleukin-13 Human genes 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 108010074109 interleukin-22 Proteins 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000013326 plasmid cotransfection Methods 0.000 claims description 2
- 229940048914 protamine Drugs 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000003151 transfection method Methods 0.000 claims description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 claims 2
- 238000005457 optimization Methods 0.000 claims 2
- 102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 claims 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 claims 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 abstract description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 210000003321 cartilage cell Anatomy 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 102000053745 human ENTPD1 Human genes 0.000 abstract 1
- 102000044916 human PTPRC Human genes 0.000 abstract 1
- 238000007885 magnetic separation Methods 0.000 abstract 1
- 210000000963 osteoblast Anatomy 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 description 22
- 210000000130 stem cell Anatomy 0.000 description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000003995 blood forming stem cell Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 210000003887 myelocyte Anatomy 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 108090001027 Troponin Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 230000009762 endothelial cell differentiation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004409 osteocyte Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002231 macronucleus Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101150010856 CRT gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024779 Comminuted Fractures Diseases 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical class OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101150039183 MYF6 gene Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 102100038380 Myogenic factor 5 Human genes 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB991175891A CN1134537C (zh) | 1999-09-08 | 1999-09-08 | 人原始间叶干细胞群的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB991175891A CN1134537C (zh) | 1999-09-08 | 1999-09-08 | 人原始间叶干细胞群的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1287166A true CN1287166A (zh) | 2001-03-14 |
CN1134537C CN1134537C (zh) | 2004-01-14 |
Family
ID=5280158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB991175891A Expired - Lifetime CN1134537C (zh) | 1999-09-08 | 1999-09-08 | 人原始间叶干细胞群的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1134537C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312277C (zh) * | 2004-04-29 | 2007-04-25 | 复旦大学附属中山医院 | 一种诱导骨髓基质细胞定向分化的方法 |
WO2008124494A1 (en) * | 2007-04-03 | 2008-10-16 | The Cleveland Clinic Foundation | Enrichment of tissue-derived adult stem cells based on retained extracellular matrix material |
CN100453640C (zh) * | 2006-04-29 | 2009-01-21 | 中国医学科学院血液学研究所 | 一种从脐带血中分离多能成体祖细胞的方法 |
CN101897724A (zh) * | 2001-12-07 | 2010-12-01 | 马克罗珀尔生物外科公司 | 制备软组织填充物的方法和制备脂肪组织移植物的方法 |
US8771678B2 (en) | 2001-12-07 | 2014-07-08 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
US8883499B2 (en) | 2001-12-07 | 2014-11-11 | Cytori Therapeutics, Inc. | Systems and methods for isolating and using clinically safe adipose derived regenerative cells |
US9480718B2 (en) | 2001-12-07 | 2016-11-01 | Cytori Therapeutics, Inc. | Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders |
US9504716B2 (en) | 2001-12-07 | 2016-11-29 | Cytori Therapeutics, Inc. | Methods of using adipose derived regenerative cells to promote restoration of intevertebral disc |
US9511094B2 (en) | 2001-12-07 | 2016-12-06 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
CN109069543A (zh) * | 2017-10-16 | 2018-12-21 | 中国科学院广州生物医药与健康研究院 | 一种重塑骨髓微环境的方法 |
-
1999
- 1999-09-08 CN CNB991175891A patent/CN1134537C/zh not_active Expired - Lifetime
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198937B2 (en) | 2001-12-07 | 2015-12-01 | Cytori Therapeutics, Inc. | Adipose-derived regenerative cells for treating liver injury |
US9504716B2 (en) | 2001-12-07 | 2016-11-29 | Cytori Therapeutics, Inc. | Methods of using adipose derived regenerative cells to promote restoration of intevertebral disc |
US9872877B2 (en) | 2001-12-07 | 2018-01-23 | Cytori Therapeutics, Inc. | Methods of using regenerative cells to promote epithelialization or neodermis formation |
US9849149B2 (en) | 2001-12-07 | 2017-12-26 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of erectile dysfunction |
US9511094B2 (en) | 2001-12-07 | 2016-12-06 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
US8771678B2 (en) | 2001-12-07 | 2014-07-08 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
US9480718B2 (en) | 2001-12-07 | 2016-11-01 | Cytori Therapeutics, Inc. | Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders |
US8883499B2 (en) | 2001-12-07 | 2014-11-11 | Cytori Therapeutics, Inc. | Systems and methods for isolating and using clinically safe adipose derived regenerative cells |
CN101897724A (zh) * | 2001-12-07 | 2010-12-01 | 马克罗珀尔生物外科公司 | 制备软组织填充物的方法和制备脂肪组织移植物的方法 |
CN1312277C (zh) * | 2004-04-29 | 2007-04-25 | 复旦大学附属中山医院 | 一种诱导骨髓基质细胞定向分化的方法 |
CN100453640C (zh) * | 2006-04-29 | 2009-01-21 | 中国医学科学院血液学研究所 | 一种从脐带血中分离多能成体祖细胞的方法 |
WO2008124494A1 (en) * | 2007-04-03 | 2008-10-16 | The Cleveland Clinic Foundation | Enrichment of tissue-derived adult stem cells based on retained extracellular matrix material |
US9045735B2 (en) | 2007-04-03 | 2015-06-02 | The Cleveland Clinic Foundation | Enrichment of tissue-derived adult stem cells based on retained extracellular matrix material |
US20100167316A1 (en) * | 2007-04-03 | 2010-07-01 | The Cleveland Clinic Foundation | Enrichment of Tissue-Derived Adult Stem Cells Based on Retained Extracellular Matrix Material |
CN109069543A (zh) * | 2017-10-16 | 2018-12-21 | 中国科学院广州生物医药与健康研究院 | 一种重塑骨髓微环境的方法 |
CN109069543B (zh) * | 2017-10-16 | 2020-02-18 | 中国科学院广州生物医药与健康研究院 | 一种重塑骨髓微环境的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1134537C (zh) | 2004-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
TWI239352B (en) | Gene transfer method with the use of serum-free medium | |
RU2205029C2 (ru) | Генетически измененные клетки и их применение для профилактики или лечения заболеваний | |
CN1838962A (zh) | 注射骨髓源细胞和培养基用于血管生成 | |
KR20090015976A (ko) | 지방 흡인 후의 지방흡인물로부터 조혈모세포의 분리 및 정제 | |
CN109097402A (zh) | 一种重组载体CAR-CD244-antiCD19的制备方法 | |
CN1134537C (zh) | 人原始间叶干细胞群的制备方法 | |
US6093393A (en) | Methods for preparing and using clonogenic fibroblasts and transfected clonogenic fibroblasts | |
CN112770768A (zh) | 用于病毒载体的生产方法 | |
CN113621611A (zh) | 一种髓系特异性启动子及其应用 | |
CN108220243B (zh) | 一种多能干细胞及其分化的t细胞和应用 | |
Donahue et al. | High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34+ cells | |
WO2023030489A1 (zh) | 经基因改造的少突胶质祖细胞在多发性硬化症中的应用 | |
WO2022247848A1 (zh) | 毛囊间充质干细胞的制备方法以及应用 | |
CN111548998B (zh) | 一种分泌pd-1抗体的长寿浆细胞及其制备方法与应用 | |
CN114941013A (zh) | 重组间充质干细胞治疗糖尿病肺炎 | |
CN107345221A (zh) | 一种TGF‑β1修饰脐带间充质干细胞的制备方法及在类风湿疾病的应用 | |
CN1225285C (zh) | 基因治疗剂 | |
WO2004071443A2 (en) | Methods and compositions for modulating stem cells | |
CN106978397A (zh) | 一种人dc-cik免疫活性细胞及其制备方法 | |
AU717974B2 (en) | Transduced human hematopoietic stem cells | |
US6984379B1 (en) | Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood | |
CN109609553A (zh) | 提高nk细胞靶向作用力的方法及ccr5基因的应用 | |
CN118240883B (zh) | 一种炎症调节能力增强型脐带间充质干细胞及其应用、制备方法 | |
Morgan et al. | Gene therapy for AIDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: He Qinghua Document name: Notification of registration; notice of patent for invention |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHAO CHUNHUA Free format text: FORMER OWNER: HE QINGHUA Effective date: 20070622 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070622 Address after: 100005 No. three, No. 5, Beijing, Dongdan Patentee after: Zhao Chunhua Address before: 266071, Huaxia Bank, 11 floor, Galaxy Building, 29 Shandong Road, Shandong, Qingdao Patentee before: He Qinghua |
|
ASS | Succession or assignment of patent right |
Owner name: JIANGSU LINGHANG STEM CELL REGENERATIVE MEDICINE E Free format text: FORMER OWNER: ZHAO CHUNHUA Effective date: 20100122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100122 Address after: Room 42, No. 610, Guangzhou Road, Nantong Development Zone, Jiangsu, China Patentee after: Jiangsu pilot stem cell regeneration medical engineering Co Ltd Address before: No. three, No. 5, Beijing, Dongdan Patentee before: Zhao Chunhua |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 226009 Jiangsu Nantong economic and Technological Development Zone and Xing Road No. 176 Patentee after: GENESIS STEMCELL REGENERATIVE MEDICINE ENGINEERING CO., LTD. Address before: 610 room 42, 226000 Guangzhou Road, Nantong Development Zone, Jiangsu, China Patentee before: Jiangsu pilot stem cell regeneration medical engineering Co Ltd |
|
CX01 | Expiry of patent term |
Granted publication date: 20040114 |
|
CX01 | Expiry of patent term |